Sandoz Group AG (0SAN)
London Exchange · UK · prices in GBP · close of 23 Oct 2026
Key indicators
| Last close | GBP 81.04 |
|---|---|
| 52-week range | 47.69 – 81.10 |
| Return, 1 month / 3 months | +13.9% / +25.9% |
| Return, 1 year / 3 years | +66.9% / +215.9% |
| Trend | Uptrend |
| RSI (14) | 79 |
| Volatility (1 year) | 30.3% |
| Worst drawdown (1 year) | -19.0% |
| Average daily value traded | 17.33M GBP |
| Dividend yield | 1.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sandoz Group is a medicines company based in Switzerland that focuses on generic drugs and biosimilars, which are lower-cost versions of medicines whose patents have expired. It develops, makes and supplies prescription medicines in many therapeutic areas, including antibiotics, cardiovascular treatments and medicines for the immune system, and it also produces biosimilar versions of complex biologic therapies. Its customers are mainly healthcare systems, hospitals, pharmacies and patients across Europe, North America and other regions of the world.
Sandoz Group AG trades under the code 0SAN on the London Exchange in UK, with its price quoted in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sandoz Group AG (0SAN) trades on the London Exchange in UK. It last closed at GBP 81.04 on 23 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 341 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 66.9% and over the last three months it rose 25.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 86 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 21.6% | ||
| From 52-week high | 0.0% | ||
| Momentum | 88 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 25.9% | ||
| 6-month return | 26.7% | ||
| 12-month return, skipping the last month | 46.5% | ||
| Stability (higher is calmer) | 68 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 30.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.0% | ||
| Liquidity | 78 · Strong | Trades actively. | |
| Average daily value traded | 17.33M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | 11 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.0% | ||
| Years with dividends | 3 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +6.4% |
|---|---|
| 1 month | +13.9% |
| 3 months | +25.9% |
| 6 months | +26.7% |
| 1 year | +66.9% |
| 3 years | +215.9% |
| 5 years | – |
Signals
| 50-day / 200-day average | 71.12 / 66.65 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.13 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 Apr 2026 | GBP 0.8000 |
| 17 Apr 2025 | GBP 0.6000 |
| 3 May 2024 | GBP 0.4500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.